Reston, VA (July 10, 2026)—New research has been published ahead-of-print by The Journal of Nuclear Medicine (JNM). JNM is published by the Society of Nuclear Medicine and Molecular Imaging, an international scientific and medical organization dedicated to advancing nuclear medicine, molecular imaging, and theranostics—precision medicine that allows diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes.
Summaries of the newly published research articles are provided below.
PET/MRI May Improve Detection of Clinically Significant Prostate Cancer
A new study evaluated whether combining multiparametric MRI with 18F-flotufolastat PET improves the detection of clinically significant prostate cancer. Researchers found the combined imaging approach outperformed MRI or PET alone and identified patients with a very high likelihood—or very low risk—of significant disease before biopsy.
PSMA PET/CT-Guided Biopsy Improves Detection of Significant Prostate Cancer
Researchers found that PSMA PET/CT–guided targeted biopsy detected more clinically significant prostate cancers than standard systematic biopsy in men with inconclusive MRI results. The study also showed that PET measurements, including SUVmax and dynamic imaging data, helped better identify aggressive disease and distinguish suspicious prostate lesions.
Real-World Study Compares Two PSMA Radiotherapies for Advanced Prostate Cancer
A study of 140 men with metastatic castration-resistant prostate cancer compared 177Lu-PSMA-617 and 177Lu-PSMA I&T under routine clinical care. Researchers examined survival, PSA responses, side effects, and factors linked to outcomes, finding similar overall survival while observing differences in biochemical response patterns and blood-count changes.
Visit the JNM website for the latest research and follow our Twitter and Facebook
